EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 20:58 (293 d 19:32 ago) – Posting: # 20959
Views: 3,348

Dear Osama,

» I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,

Complete thread:

 Admin contact
21,076 posts in 4,394 threads, 1,469 registered users;
online 5 (1 registered, 4 guests [including 2 identified bots]).
Forum time: Saturday 17:31 CEST (Europe/Vienna)

For every fact
there is an infinity of hypotheses.    Robert M. Pirsig

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz